# Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial

> **Newsylist Open Intelligence Dossier** · First detected: 2026-06-23 15:05 UTC · Category: Business · Sources: 7 · Current Velocity: 5.29

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Yahoo Finance | Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC | 2026-06-23 11:15 | [Source Link](https://news.google.com/rss/articles/CBMikwFBVV95cUxONXNxb3dkYXhCUXBfY21uZ2c5dDY1UTQ3emZlVnpaZTExRDI1bHp6XzY4ZHM4YkJrVkdjajJkU1dxLWdQQWg1NTQ4eGZ6WmNzSi1kZ2t6aWdjV1cwbGdHSzZ0SEJzSmFEc0o2MjM1N0tmRnhLalBBTnM4NlRsc0xjTzVWOGRIekxjeHJ4ZEtEa05jMWs?oc=5) |
| Reuters | Pfizer's experimental drug misses main goal of lung cancer trial | 2026-06-23 11:15 | [Source Link](https://news.google.com/rss/articles/CBMizAFBVV95cUxOYjhaR2JUWVBWVi1YODRGN0luVlpsQUI4UXNtSzNJcTRSMDllNzdDN0EyUHZMVmV2YXRadjloLW9Pb3Mxc1FYQUxmamFQN2VEM1dBM1BpQ1ZGUmpRTmp0a2J2YjRXcVJETFBFYWIzSTNFV0QzR2U1UlZHTHRPbERKOXAwV29WRHhIcGp6R3YtZkZjb2xqdzVIWDM3TlBvbWRRTHVUXzBzTWZ4SXVPN1R3OUNNY0VJVVBKNEpBUWtRNUpSY0VYVTlYZTlmaDQ?oc=5) |
| Kalkine Media | Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle? | 2026-06-23 11:15 | [Source Link](https://news.google.com/rss/articles/CBMingFBVV95cUxPdy12OTNHdTZudXJaWXRVaVZiRzRLLTUwVG54N3BBeWNSOTdJeG9xZy1hQUtTRlhnTW9tOEJkbnpuck9LZkRablI4RzIxRnJaaHZUTDF4aWhzaW5XU00xblg2Z21tSWt3LUFWUnMwUTZoRlVRTUVhV0YyY0ZxOS1uN2lyRGtyQkFpazhacUZPS3hLRGNFMVJWdUpmYjlfdw?oc=5) |
| CancerNetwork | Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial | 2026-06-23 11:15 | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxNcDV1WVRhLVhGY2NRLWdNVHJod2NHbVlnOFhIcm9LakZubk1SU3AzandubWpWdGU4WkFxZEc0V05DZi1YWUg0aEMwX2FhVy1Od0tiZzRDRFlBWVFpTUhwV3NmUkszZ2dMRzVmNHVla0t0cUJQQjhyMnRaZXJQS1F6M0VwR09LZkM3ZlVKV3lwcEstcl9SODlQVlByNVN6dVlQTmljRXZXeXdGRHF6?oc=5) |
| BioPharma Dive | Pfizer drug acquired in Seagen deal disappoints in lung cancer study | 2026-06-23 11:15 | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxNWkFfUV9pVjVZRFJqQ0JHRXM5VHVNMEsyVko0VDhybTRYVC1LWVhJS2lLR0xOenRlRGM3aXk5enhYQUgzdFRJMEJsaEZocDZkVkRqQUNkT3Bwdkc2Yy14RVJtYXpKVktWOC0yUGtaS040dmUwNFFkeXB0T2M5SjhHUFB5YUtCSC1QRXhZdGdPWkl4ZDN1LUszbnBsQQ?oc=5) |
| OncLive | Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC | 2026-06-23 11:15 | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxQYlQ2aDNQdjhNZXNRNFpWUFRxQ204NjRCbVU1RmJBZklscGJIampZTEZwc25sdjdOTW53d1Z0UEdkN09TUVhDM0txampGSEtWVmZhUnlkZDYxME9kVFFEWUtpNjgwZ3dUclVWLXQ0aUdheHVyRTZiZFVUVnRSWjJ4VlVHRlpya2pzNTZ5VGZrYWJRUXlLcmJ1SnJpc3NvWmZ2dVZKYlNkbmhIOHd5?oc=5) |
| Yahoo Finance | PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug | 2026-06-23 11:15 | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxOQkE1T3pDZDYxN2g5UWNrRUFSUjVRdGotak9YMTF4VVZhQ3NFMFctREUyZTB6cG5GclVIWW5mWVAzaVVJZE1KTWhPMkluOUp6dlI5ckhXeWVJS2h2S1NITVp6eWxjMGRuQ3A1WnZRNmZpUHEyYjJfUkdIVE5JRlVabVVPUU0wVGRzNzhSZEUtSUJKQmRRVGc?oc=5) |
| Endpoints News | Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial | 2026-06-23 11:15 | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxNcG5fWWpvWDNFZWM0OEUxbmgtbU0wTDgzQjNQTE12QkVMdTFlMlliUFlwTkNsbUY4T0FPYXdONkx6cWU1a3pxSWJ2UjcwLUgxQWJuVnFBdG9ya2VmV1hVRmkyRXhqelp4ckFqY0JlcVBqR29WMzg5cWR1VVpfNUU1cjVZVXVfRXlsNmt0X2phVmRiQ05BMXhESVJRMmw5YlE?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-06-23/pfizer-s-first-new-adc-from-seagen-acquisition-fails-phase-3-nsclc-trial*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*